Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma.

Qibiao Wu Haley Ellis Giulia Siravegna Alexa G Michel Bryanna L Norden Ferran Fece de la Cruz Eranga Roshan Balasooriya Yuanli Zhen Vanessa Silva Silveira Jianwei Che Ryan B Corcoran Nabeel El-Bardeesy

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

These data support secondary FGFR2 mutations as the primary mode of acquired resistance to FGFR inhibitors-most commonly N550 and V565 mutations. Thus, development of combination strategies and next-generation FGFR inhibitors targeting the full spectrum of FGFR2 resistance mutations will be critical.

Keyphrases

electronic health record
drug delivery
data analysis